Use of an in vivo model to determine the effects of interleukin-1 on cells at different stages in the osteoclast lineage
- 1 February 1995
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 10 (2) , 295-301
- https://doi.org/10.1002/jbmr.5650100217
Abstract
In vitro model systems have been used extensively to study factors that affect osteoclast formation and to identify osteoclast precursors. However, in vitro systems do not examine the entire process of osteoclast differentiation simultaneously and lack accessory cells normally present in vivo. Additionally, the role that metabolism of the factor may play on its osteotropic activity in vivo is not addressed by these culture systems. Therefore, we have developed an in vivo model that permits us to examine simultaneously the effects of osteotropic factors on three distinct stages of osteoclast differentiation: (1) multipotent osteoclast precursors, the granulocyte‐macrophage colony‐forming unit (CFU‐GM); (2) more differentiated marrow mononuclear osteoclast precursors; and (3) mature osteoclasts already present on bone surfaces. In the current study, we used interleukin‐1 (IL‐1) as a prototypic osteotropic factor to test the utility of this system to delineate the cellular mechanisms responsible for enhanced osteoclast activity stimulated by this cytokine. IL‐1 induced hypercalcemia and enhanced the growth and differentiation of CFU‐GM, increased the number of more committed mononuclear osteoclast precursors, and stimulated mature osteoclasts to resorb bone. These data demonstrate that this simple in vivo model permits the easy delineation of the stages of osteoclast development, in which osteotropic factors act to enhance bone turnover, and may be useful in understanding the mechanism of action of antiresorptive agents.Keywords
Funding Information
- Research Funds from the Veterans Administration (AR 39539, AR 41336)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AM 35188)
- National Institute of Diabetes, Digestive, and Kidney Disease (CA 40035)
- National Cancer Institute (DE08569)
- National Institute of Dental Research
This publication has 25 references indexed in Scilit:
- Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6Science, 1992
- Perspectives: Interleukin-6: An osteotropic factor?Journal of Bone and Mineral Research, 1992
- 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.Journal of Clinical Investigation, 1992
- Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.Journal of Clinical Investigation, 1992
- Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineageJournal of Bone and Mineral Research, 1990
- Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease.Journal of Clinical Investigation, 1990
- Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.Journal of Clinical Investigation, 1990
- Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.Journal of Clinical Investigation, 1989
- Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitroJournal of Bone and Mineral Research, 1989
- Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts.The Journal of Experimental Medicine, 1986